# Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury

> **NCT01676441** · PHASE2,PHASE3 · TERMINATED · sponsor: **Pharmicell Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Spinal Cord Injury

## Interventions

- **DRUG:** cellgram-spine

## Key facts

- **NCT ID:** NCT01676441
- **Lead sponsor:** Pharmicell Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2021-03-04
- **Final completion:** 2021-03-04
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** sponsor decision (confidential)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676441, "Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01676441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*